Real-world study of inetetamab for advanced her2 breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called inetetamab for people with HER2-positive breast cancer that has spread or cannot be removed. It aims to see how well the drug works as a first treatment, potentially helping to control the cancer and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HER2-positive (a protein that helps cancer grow) and has spread or cannot be removed by surgery.
- You have at least one tumor that can be measured on a scan.
- You are in good enough physical condition to carry on daily activities (ECOG score 0 or 1).
- You have not had chemotherapy for advanced breast cancer, but you may have had hormone therapy.
- Your heart, liver, and blood counts meet basic health standards.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted therapies (inetetamab plus rapamycin) with chemotherapy for HER2-positive breast cancer that has spread or come back and has a specific genetic change (PAM pathway mutation). It aims to see if this combination can work better than current treatments for people whose cancer has progressed after trastuzumab.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
This trial is testing an investigational drug called inetetamab (which targets HER2) combined with chemotherapy, and sometimes also an immunotherapy drug (PD-1/PD-L1 inhibitor). It aims to see if this combination helps people with advanced HER2-positive biliary tract cancer live longer and shrink their tumors.
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.